Literature DB >> 30214092

Primary hepatic carcinosarcoma with multimodal treatment.

Daisuke Kurita1, Yasuji Mokuno1, Hideo Matsubara1, Hirokazu Kaneko1, Mikihiro Shamoto2, Akira Satou3, Shinsuke Iyomasa1.   

Abstract

Hepatic carcinosarcoma (HCS) generally presents in advanced stages, demonstrates aggressive behavior, and has a poor prognosis. Other than curative primary resection, no effective treatment options exist. We present a case of resected HCS with four repeat resections for solitary lymph node recurrence followed by chemoradiotherapy with doxorubicin and ifosfamide. A 67-year-old Japanese man was admitted to our hospital for evaluation of an asymptomatic hepatic tumor. The patient underwent right hepatectomy with a presumptive preoperative diagnosis of atypical hepatocellular carcinoma. Based on histopathological and immunohistochemical findings, the tumor was diagnosed as HCS containing osteosarcoma and chondrosarcoma components. After the initial surgery, the patient underwent four additional resections for solitary lymph node HCS recurrence, and then underwent chemoradiotherapy with doxorubicin and ifosfamide for an unresectable lymph node recurrence. Chemotherapy was stopped after two cycles because of severe adverse events, although chemoradiotherapy markedly reduced the size of the lymph node recurrence and provided a progression-free survival of 12 months. Thirty-seven months after the initial surgery, the patient died of cardiac invasion of multiple mediastinal lymph node metastases. The clinical course outlined in this case report suggests that chemoradiotherapy with doxorubicin and ifosfamide for metastatic HCS may prolong survival in patients with unresectable lesions.

Entities:  

Keywords:  chemoradiotherapy; doxorubicin; hepatic carcinosarcoma; ifosfamide

Mesh:

Substances:

Year:  2018        PMID: 30214092      PMCID: PMC6125652          DOI: 10.18999/nagjms.80.3.423

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  16 in total

1.  Surgical resection of a solitary para-aortic lymph node metastasis from hepatocellular carcinoma.

Authors:  Junji Ueda; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Sho Mineta; Masato Yoshioka; Youichi Kawano; Tetsuya Shimizu; Etsuko Hara; Chiaki Kawamoto; Keiko Kaneko; Eiji Uchida
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Authors:  Nabeel Pervaiz; Nigel Colterjohn; Forough Farrokhyar; Richard Tozer; Alvaro Figueredo; Michelle Ghert
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

3.  Carcinosarcoma of the liver.

Authors:  Hideaki Goto; Atsushi Tanaka; Fukuo Kondo; Koji Takeshita; Ikuo Nagashima; Naoko Hanawa; Mitsuhiko Aiso; Yoriyuki Takamori; Ken-ichiro Kato; Yoshihisa Takahashi; Jun-ichi Fukushima; Shigeru Furui; Toshio Fukusato; Takehide Asano; Hajime Takikawa
Journal:  Intern Med       Date:  2010-12-01       Impact factor: 1.271

4.  Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.

Authors:  Gunjal Garg; Jay P Shah; Sanjeev Kumar; Christopher S Bryant; Adnan Munkarah; Robert T Morris
Journal:  Int J Gynecol Cancer       Date:  2010-07       Impact factor: 3.437

5.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Authors:  Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

6.  Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis.

Authors:  Franziska Eckert; Christiane Matuschek; Arndt-Christian Mueller; Martin Weinmann; Joerg T Hartmann; Claus Belka; Wilfried Budach
Journal:  Radiat Oncol       Date:  2010-06-16       Impact factor: 3.481

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 8.  Long-term recurrence-free survival in a patient with primary hepatic carcinosarcoma: case report with a literature review.

Authors:  Yusuke Yamamoto; Hidenori Ojima; Kazuaki Shimada; Hiroaki Onaya; Nobuyoshi Hiraoka; Yasunori Mizuguchi; Tomoo Kosuge; Yae Kanai
Journal:  Jpn J Clin Oncol       Date:  2009-10-03       Impact factor: 3.019

9.  Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.

Authors:  Jonathan L Wright; Peter C Black; Gordon A Brown; Michael P Porter; Ashish M Kamat; Colin P Dinney; Daniel W Lin
Journal:  J Urol       Date:  2007-10-15       Impact factor: 7.450

10.  Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.

Authors:  V H Bramwell; D Anderson; M L Charette
Journal:  Sarcoma       Date:  2000
View more
  2 in total

1.  The Clinicopathological and Imaging Characteristics of Primary Hepatic Carcinosarcoma and a Review of the Literature.

Authors:  Fengli Bin; Zhihong Chen; Peng Liu; Jianbin Liu; Zhiqun Mao
Journal:  J Hepatocell Carcinoma       Date:  2020-10-13

2.  Primary Exophytic Extraskeletal Osteosarcoma of the Liver: A Case Report and Literature Review.

Authors:  Jing Zhang; Xiuchao He; Wenying Yu; Fuming Ying; Jun Cai; Shengde Deng
Journal:  Risk Manag Healthc Policy       Date:  2021-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.